Related Experiment Videos
ACAT inhibition and amyloid beta reduction.
Raja Bhattacharyya1, Dora M Kovacs
1Neurobiology of Disease Laboratory, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Diseases (MIND), Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
Biochimica Et Biophysica Acta
|April 20, 2010
Summary
Inhibiting acyl-coenzyme A: cholesterol acyl-transferase 1 (ACAT1) may reduce beta-amyloid (Abeta) production. This offers a potential therapeutic strategy for Alzheimer's disease (AD) by targeting cholesterol distribution.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Alzheimer's disease (AD) is characterized by beta-amyloid (Abeta) peptide accumulation.
- Intracellular cholesterol levels and distribution critically influence Abeta generation.
- Acyl-coenzyme A: cholesterol acyl-transferase (ACAT) enzymes regulate cellular cholesterol distribution.
Purpose of the Study:
- To investigate ACAT1 as a therapeutic target for reducing Abeta production.
- To explore the role of ACAT inhibition in Alzheimer's disease treatment.
Main Methods:
- Utilized pharmacological ACAT inhibitors.
- Employed transgenic animal models of Alzheimer's disease.
Main Results:
- ACAT1 inhibition was identified as a key factor in lowering Abeta generation.
- ACAT1 plays a significant role in regulating the cellular distribution of cholesterol relevant to Abeta production.
Conclusions:
- ACAT1 inhibition presents a promising therapeutic strategy for Alzheimer's disease.
- Targeting ACAT1 may effectively reduce Abeta accumulation and deposition.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
707
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
707
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.4K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.4K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.3K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.3K